Use of Osteoporosis Medications after Hospitalization for Hip Fracture: A Cross-national Study
Abstract Background Although current osteoporosis management guidelines recommend use of pharmacologic treatment after hip fracture, the care of such patients has been suboptimal. The objective of this cross-national study was to quantify the use of and adherence to osteoporosis medication after hip...
Saved in:
| Published in | The American journal of medicine Vol. 128; no. 5; pp. 519 - 526.e1 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Elsevier Inc
01.05.2015
Elsevier Sequoia S.A |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Abstract Background Although current osteoporosis management guidelines recommend use of pharmacologic treatment after hip fracture, the care of such patients has been suboptimal. The objective of this cross-national study was to quantify the use of and adherence to osteoporosis medication after hip fracture in 3 countries with different healthcare systems—the United States, Korea, and Spain. Methods In 3 cohorts of patients aged ≥65 years hospitalized for hip fracture, we calculated the proportion receiving ≥1 osteoporosis drug after discharge. Adherence to osteoporosis treatment was measured as the proportion of days covered (PDC) during the first year after the hip fracture. Results We identified 86,202 patients with a hip fracture: 4704 (US Medicare), 6700 (US commercial), 57,631 (Korea), and 17,167 (Spain). The mean age was 77-83 years, and 74%-78% were women. In the year before the index hip fracture, 16%-18% were taking an osteoporosis medication. Within 3 months after the index hip fracture, 11% (US Medicare), 13% (US commercial), 39% (Korea), and 25% (Spain) of patients filled ≥1 prescription for osteoporosis medication. For those who filled ≥1 prescriptions for an osteoporosis medication, the mean PDC in the year after the fracture was 0.70 (US Medicare), 0.67 (US commercial), 0.43 (Korea), and 0.66 (Spain). Conclusions Regardless of differences in healthcare delivery systems and medication reimbursement plans, the use of osteoporosis medications for the secondary prevention of osteoporotic fracture was low. Adherence to osteoporosis treatment was also suboptimal, with the PDC <0.70 in all 3 countries. |
|---|---|
| AbstractList | Although current osteoporosis management guidelines recommend use of pharmacologic treatment after hip fracture, the care of such patients has been suboptimal. The objective of this cross-national study was to quantify the use of and adherence to osteoporosis medication after hip fracture in 3 countries with different healthcare systems—the United States, Korea, and Spain.
In 3 cohorts of patients aged ≥65 years hospitalized for hip fracture, we calculated the proportion receiving ≥1 osteoporosis drug after discharge. Adherence to osteoporosis treatment was measured as the proportion of days covered (PDC) during the first year after the hip fracture.
We identified 86,202 patients with a hip fracture: 4704 (US Medicare), 6700 (US commercial), 57,631 (Korea), and 17,167 (Spain). The mean age was 77-83 years, and 74%-78% were women. In the year before the index hip fracture, 16%-18% were taking an osteoporosis medication. Within 3 months after the index hip fracture, 11% (US Medicare), 13% (US commercial), 39% (Korea), and 25% (Spain) of patients filled ≥1 prescription for osteoporosis medication. For those who filled ≥1 prescriptions for an osteoporosis medication, the mean PDC in the year after the fracture was 0.70 (US Medicare), 0.67 (US commercial), 0.43 (Korea), and 0.66 (Spain).
Regardless of differences in healthcare delivery systems and medication reimbursement plans, the use of osteoporosis medications for the secondary prevention of osteoporotic fracture was low. Adherence to osteoporosis treatment was also suboptimal, with the PDC <0.70 in all 3 countries. Abstract Background Although current osteoporosis management guidelines recommend use of pharmacologic treatment after hip fracture, the care of such patients has been suboptimal. The objective of this cross-national study was to quantify the use of and adherence to osteoporosis medication after hip fracture in 3 countries with different healthcare systems—the United States, Korea, and Spain. Methods In 3 cohorts of patients aged ≥65 years hospitalized for hip fracture, we calculated the proportion receiving ≥1 osteoporosis drug after discharge. Adherence to osteoporosis treatment was measured as the proportion of days covered (PDC) during the first year after the hip fracture. Results We identified 86,202 patients with a hip fracture: 4704 (US Medicare), 6700 (US commercial), 57,631 (Korea), and 17,167 (Spain). The mean age was 77-83 years, and 74%-78% were women. In the year before the index hip fracture, 16%-18% were taking an osteoporosis medication. Within 3 months after the index hip fracture, 11% (US Medicare), 13% (US commercial), 39% (Korea), and 25% (Spain) of patients filled ≥1 prescription for osteoporosis medication. For those who filled ≥1 prescriptions for an osteoporosis medication, the mean PDC in the year after the fracture was 0.70 (US Medicare), 0.67 (US commercial), 0.43 (Korea), and 0.66 (Spain). Conclusions Regardless of differences in healthcare delivery systems and medication reimbursement plans, the use of osteoporosis medications for the secondary prevention of osteoporotic fracture was low. Adherence to osteoporosis treatment was also suboptimal, with the PDC <0.70 in all 3 countries. Although current osteoporosis management guidelines recommend use of pharmacologic treatment after hip fracture, the care of such patients has been suboptimal. The objective of this cross-national study was to quantify the use of and adherence to osteoporosis medication after hip fracture in 3 countries with different healthcare systems—the United States, Korea, and Spain. In 3 cohorts of patients aged ≥65 years hospitalized for hip fracture, we calculated the proportion receiving ≥1 osteoporosis drug after discharge. Adherence to osteoporosis treatment was measured as the proportion of days covered (PDC) during the first year after the hip fracture. We identified 86,202 patients with a hip fracture: 4704 (US Medicare), 6700 (US commercial), 57,631 (Korea), and 17,167 (Spain). The mean age was 77-83 years, and 74%-78% were women. In the year before the index hip fracture, 16%-18% were taking an osteoporosis medication. Within 3 months after the index hip fracture, 11% (US Medicare), 13% (US commercial), 39% (Korea), and 25% (Spain) of patients filled ≥1 prescription for osteoporosis medication. For those who filled ≥1 prescriptions for an osteoporosis medication, the mean PDC in the year after the fracture was 0.70 (US Medicare), 0.67 (US commercial), 0.43 (Korea), and 0.66 (Spain). Regardless of differences in healthcare delivery systems and medication reimbursement plans, the use of osteoporosis medications for the secondary prevention of osteoporotic fracture was low. Adherence to osteoporosis treatment was also suboptimal, with the PDC <0.70 in all 3 countries. BACKGROUNDAlthough current osteoporosis management guidelines recommend use of pharmacologic treatment after hip fracture, the care of such patients has been suboptimal. The objective of this cross-national study was to quantify the use of and adherence to osteoporosis medication after hip fracture in 3 countries with different healthcare systems—the United States, Korea, and Spain.METHODSIn 3 cohorts of patients aged ≥65 years hospitalized for hip fracture, we calculated the proportion receiving ≥1 osteoporosis drug after discharge. Adherence to osteoporosis treatment was measured as the proportion of days covered (PDC) during the first year after the hip fracture.RESULTSWe identified 86,202 patients with a hip fracture: 4704 (US Medicare), 6700 (US commercial), 57,631 (Korea), and 17,167 (Spain). The mean age was 77-83 years, and 74%-78% were women. In the year before the index hip fracture, 16%-18% were taking an osteoporosis medication. Within 3 months after the index hip fracture, 11% (US Medicare), 13% (US commercial), 39% (Korea), and 25% (Spain) of patients filled ≥1 prescription for osteoporosis medication. For those who filled ≥1 prescriptions for an osteoporosis medication, the mean PDC in the year after the fracture was 0.70 (US Medicare), 0.67 (US commercial), 0.43 (Korea), and 0.66 (Spain).CONCLUSIONSRegardless of differences in healthcare delivery systems and medication reimbursement plans, the use of osteoporosis medications for the secondary prevention of osteoporotic fracture was low. Adherence to osteoporosis treatment was also suboptimal, with the PDC <0.70 in all 3 countries. Although current osteoporosis management guidelines recommend use of pharmacologic treatment after hip fracture, the care of such patients has been suboptimal. The objective of this cross-national study was to quantify the use of and adherence to osteoporosis medication after hip fracture in 3 countries with different healthcare systems--the United States, Korea, and Spain. In 3 cohorts of patients aged ≥65 years hospitalized for hip fracture, we calculated the proportion receiving ≥1 osteoporosis drug after discharge. Adherence to osteoporosis treatment was measured as the proportion of days covered (PDC) during the first year after the hip fracture. We identified 86,202 patients with a hip fracture: 4704 (US Medicare), 6700 (US commercial), 57,631 (Korea), and 17,167 (Spain). The mean age was 77-83 years, and 74%-78% were women. In the year before the index hip fracture, 16%-18% were taking an osteoporosis medication. Within 3 months after the index hip fracture, 11% (US Medicare), 13% (US commercial), 39% (Korea), and 25% (Spain) of patients filled ≥1 prescription for osteoporosis medication. For those who filled ≥1 prescriptions for an osteoporosis medication, the mean PDC in the year after the fracture was 0.70 (US Medicare), 0.67 (US commercial), 0.43 (Korea), and 0.66 (Spain). Regardless of differences in healthcare delivery systems and medication reimbursement plans, the use of osteoporosis medications for the secondary prevention of osteoporotic fracture was low. Adherence to osteoporosis treatment was also suboptimal, with the PDC <0.70 in all 3 countries. |
| Author | Park, Byung-Joo, MD, PhD Kim, Mi-Sook, PhD Avorn, Jerry, MD Peiró, Salvador, MD, PhD Sanfélix-Gimeno, Gabriel, PharmD, PhD Hurtado, Isabel, PhD Song, Hong Ji, MD, PhD Lee, Joongyub, MD, PhD Liu, Jun, MD, MPH Choi, Nam-Kyong, PhD Kim, Seoyoung C., MD, ScD, MSCE |
| AuthorAffiliation | 2 Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea 6 Korea Institute of Drug Safety and Risk Management, Seoul, Korea 3 Health Services Research Unit, Center for Public Health Research; Red de Investigación en Servicios de Salud en Enfermedades Crónicas, Valencia, Spain 1 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA 5 Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea 4 Department of Family Medicine, Health Promotion Center, Hallym University Sacred Heart Hospital, Anyang, Korea |
| AuthorAffiliation_xml | – name: 4 Department of Family Medicine, Health Promotion Center, Hallym University Sacred Heart Hospital, Anyang, Korea – name: 6 Korea Institute of Drug Safety and Risk Management, Seoul, Korea – name: 2 Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea – name: 1 Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA – name: 3 Health Services Research Unit, Center for Public Health Research; Red de Investigación en Servicios de Salud en Enfermedades Crónicas, Valencia, Spain – name: 5 Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea |
| Author_xml | – sequence: 1 fullname: Kim, Seoyoung C., MD, ScD, MSCE – sequence: 2 fullname: Kim, Mi-Sook, PhD – sequence: 3 fullname: Sanfélix-Gimeno, Gabriel, PharmD, PhD – sequence: 4 fullname: Song, Hong Ji, MD, PhD – sequence: 5 fullname: Liu, Jun, MD, MPH – sequence: 6 fullname: Hurtado, Isabel, PhD – sequence: 7 fullname: Peiró, Salvador, MD, PhD – sequence: 8 fullname: Lee, Joongyub, MD, PhD – sequence: 9 fullname: Choi, Nam-Kyong, PhD – sequence: 10 fullname: Park, Byung-Joo, MD, PhD – sequence: 11 fullname: Avorn, Jerry, MD |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25660252$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUk1v1DAQtVAR3Rb-AUKWuHDJ4s_E4YBUrShFKuqhVOKE5TgTcMjGqe1UWn49Tre00AvSSLbHb57nzfMROhj9CAi9pGRNCS3f9muz7bfQrhmhck1oDvEEraiUsqhoyQ7QihDCipoLfoiOYuzzkdSyfIYOmSxLwiRboW9XEbDv8EVM4CcffHQRf4bWWZOcHyM2XYKAz3ycXDKD-3Wbxp3POTfh02BsmgO8wyd4k4tjMd4CzIAv09zunqOnnRkivLhbj9HV6Ycvm7Pi_OLjp83JeWFLylIhAGrF2twclaJRYIlqrWqBUGYboYBLaWTDJQMClTKyNnXTVpZz2xgi6oYfo_d73mlu8kwsjCmYQU_BbU3YaW-c_vdmdD_0d3-jhaBC1SoTvLkjCP56hpj01kULw2BG8HPUtKwqXlUZnKGvH0F7P4cseUEpVoqSC5ZRYo-yy1gCdPfNUKIXA3Wv9wbqxUBNaA6Ry179LeS-6I9jD0ohj_PGQdDROhhttiyATbr17n8vPCawgxuz38NP2EF80KIj00RfLp9o-UNU5p2qvvLficXF6Q |
| CODEN | AJMEAZ |
| CitedBy_id | crossref_primary_10_1080_17446651_2017_1256199 crossref_primary_10_1002_art_39546 crossref_primary_10_1007_s11657_021_00992_9 crossref_primary_10_1001_jamanetworkopen_2018_0826 crossref_primary_10_1111_jgs_17381 crossref_primary_10_1002_jbmr_2832 crossref_primary_10_1007_s00198_020_05742_0 crossref_primary_10_1007_s00264_017_3639_3 crossref_primary_10_1007_s11606_021_06938_8 crossref_primary_10_1007_s11657_023_01314_x crossref_primary_10_1002_acr_24171 crossref_primary_10_1080_17482631_2017_1307061 crossref_primary_10_3899_jrheum_180889 crossref_primary_10_1016_j_maturitas_2017_06_021 crossref_primary_10_1002_jbmr_4028 crossref_primary_10_1093_qjmed_hcx216 crossref_primary_10_1186_s12872_018_0757_9 crossref_primary_10_1002_cmdc_201900034 crossref_primary_10_1302_0301_620X_101B11_BJJ_2019_0387_R1 crossref_primary_10_32414_0869_8678_2017_1_47_57 crossref_primary_10_1016_S1169_8330_19_30352_7 crossref_primary_10_1097_BOR_0000000000000363 crossref_primary_10_1007_s00402_023_05132_1 crossref_primary_10_1007_s00198_018_4553_2 crossref_primary_10_1016_S0140_6736_18_32112_3 crossref_primary_10_1007_s11914_019_00547_5 crossref_primary_10_1136_bmjopen_2020_047258 crossref_primary_10_1038_s41598_017_10899_6 crossref_primary_10_1007_s00198_021_05900_y crossref_primary_10_1007_s11657_021_00988_5 crossref_primary_10_1007_s11657_017_0317_4 crossref_primary_10_1007_s00774_020_01093_2 crossref_primary_10_1007_s40264_018_0651_5 crossref_primary_10_1007_s11657_022_01179_6 crossref_primary_10_1007_s11657_020_00816_2 crossref_primary_10_2217_ijr_15_31 crossref_primary_10_1038_s41598_022_13465_x crossref_primary_10_17816_vto201724147_57 crossref_primary_10_1016_j_injury_2020_11_041 crossref_primary_10_1007_s00198_020_05324_0 crossref_primary_10_1007_s00198_019_05197_y crossref_primary_10_1007_s11657_021_00930_9 crossref_primary_10_1007_s40520_020_01486_3 crossref_primary_10_1093_ije_dyz266 crossref_primary_10_1007_s00198_015_3261_4 crossref_primary_10_1016_j_afos_2016_02_002 crossref_primary_10_1007_s11657_019_0612_3 crossref_primary_10_1016_j_oooo_2022_04_049 crossref_primary_10_1007_s00198_022_06298_x crossref_primary_10_1016_j_afos_2017_05_001 crossref_primary_10_1111_jep_13164 crossref_primary_10_1371_journal_pone_0160661 crossref_primary_10_1001_jamanetworkopen_2018_0844 crossref_primary_10_1007_s00198_019_05074_8 crossref_primary_10_1007_s00198_022_06482_z crossref_primary_10_1007_s00198_024_07036_1 crossref_primary_10_1007_s11657_023_01330_x crossref_primary_10_3389_fphar_2019_00768 crossref_primary_10_1016_j_amjmed_2017_02_042 crossref_primary_10_1210_clinem_dgab570 crossref_primary_10_1002_jbmr_4562 crossref_primary_10_7326_M19_0961 crossref_primary_10_1007_s11657_022_01201_x crossref_primary_10_1371_journal_pone_0278368 crossref_primary_10_1016_j_fertnstert_2019_09_038 crossref_primary_10_1007_s11657_021_00946_1 crossref_primary_10_1055_s_0041_1731635 crossref_primary_10_1002_jbmr_3074 crossref_primary_10_7759_cureus_35407 crossref_primary_10_1007_s11657_019_0662_6 crossref_primary_10_1007_s11657_020_00798_1 crossref_primary_10_1007_s40520_016_0681_8 crossref_primary_10_1007_s10266_018_0362_5 crossref_primary_10_1007_s11657_020_00859_5 crossref_primary_10_1007_s00198_019_05066_8 crossref_primary_10_1016_j_eprac_2022_09_002 crossref_primary_10_1002_jbmr_3067 crossref_primary_10_1007_s00198_021_05864_z crossref_primary_10_1007_s11657_017_0307_6 crossref_primary_10_1007_s40520_023_02682_7 crossref_primary_10_1042_CS20160010 crossref_primary_10_21615_cesmedicina_34_1_2 crossref_primary_10_1007_s00198_020_05341_z crossref_primary_10_2217_cer_2020_0216 crossref_primary_10_1210_clinem_dgad345 crossref_primary_10_1586_14737167_2016_1171145 crossref_primary_10_1016_j_afos_2018_11_084 crossref_primary_10_1007_s41999_018_0028_4 crossref_primary_10_4158_EP_2018_0082 crossref_primary_10_1016_j_nurpra_2019_10_017 crossref_primary_10_3390_ijms23169465 crossref_primary_10_1007_s11657_019_0657_3 |
| Cites_doi | 10.2106/JBJS.G.00864 10.1007/s00198-010-1473-1 10.1136/bmj.327.7418.771 10.1002/jbmr.533 10.1001/jama.2009.1462 10.1002/jbmr.1893 10.1002/jbmr.1698 10.1007/s00198-006-0172-4 10.1016/S0140-6736(96)07088-2 10.1002/jbmr.2202 10.1056/NEJMoa067312 10.2106/00004623-200208000-00008 10.1056/NEJMoa074941 10.1001/archinte.1997.00440430099012 10.2106/JBJS.L.01781 10.1007/s11914-009-0006-3 10.1007/s00198-012-2034-6 10.1016/j.semarthrit.2005.11.001 10.1007/s00198-013-2365-y 10.1007/s00198-012-2024-8 10.2106/JBJS.I.01132 10.1007/s00198-013-2420-8 10.1038/nrrheum.2011.60 10.1056/NEJM200507073530120 |
| ContentType | Journal Article |
| Copyright | Elsevier Inc. 2015 Elsevier Inc. Copyright © 2015 Elsevier Inc. All rights reserved. Copyright Elsevier Science Ltd. May 2015 |
| Copyright_xml | – notice: Elsevier Inc. – notice: 2015 Elsevier Inc. – notice: Copyright © 2015 Elsevier Inc. All rights reserved. – notice: Copyright Elsevier Science Ltd. May 2015 |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7TK 7TO 7TS 7U9 H94 K9. 7X8 5PM |
| DOI | 10.1016/j.amjmed.2015.01.014 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts Neurosciences Abstracts Oncogenes and Growth Factors Abstracts Physical Education Index Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Neurosciences Abstracts Physical Education Index MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Virology and AIDS Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1555-7162 |
| EndPage | 526.e1 |
| ExternalDocumentID | 3692952251 10_1016_j_amjmed_2015_01_014 25660252 S000293431500087X 1_s2_0_S000293431500087X |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States Republic of Korea Spain United States--US South Korea |
| GeographicLocations_xml | – name: Republic of Korea – name: Spain – name: United States – name: South Korea – name: United States--US |
| GrantInformation_xml | – fundername: Pfizer funderid: http://dx.doi.org/10.13039/100004319 – fundername: National Institutes of Health grantid: K23 AR059677 funderid: http://dx.doi.org/10.13039/100000002 – fundername: NIAMS NIH HHS grantid: K23 AR059677 |
| GroupedDBID | - 08R 0R 1- 123 1B1 1P 1RT 1~5 23M 3O- 4 4.4 457 4CK 4G. 53G 55 5RE 5VS 68V 6J9 7-5 AACTN AAEDT AAIAV AALRI AAQFI AAQQT AAQXK AAWTL AAXUO AAYOK ABFLS ABLJU ABMAC ABOCM ABPPZ ABPTK ABWYI ACGFO ACIUM ACKOT ACPRK ADBBV ADPAM AENEX AEVXI AFFNX AFHKK AFRHN AFTJW AGHFR AGZHU AHHHB AHMBA AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS ALXNB AMRAJ ASPBG AVWKF AZFZN BELOY BKOMP C5W CS3 EBS EFJIC EJD EX3 F5P FDB FEDTE FGOYB FIRID FO G-2 G-Q GBLVA GJ HEA HMK HMO HVGLF HZ IH2 IHE IPNFZ J1W J5H K K-O KOM L7B LZ2 M29 M41 MO0 MVM N4W N9A NCXOZ NQ- O9- OD. OHT OO P2P PC. PQEST PQQKQ R2- RIG ROL RPZ SAE SEL SES SSZ TWZ UBY UHB UHU UNMZH UV1 WH7 WOW WUQ X X7M XH2 XPP YFH YOC YQJ YYQ Z5R ZA5 ZGI ZUP ZXP --- --K -~X .-4 .1- .55 .FO .GJ 0R~ 1CY 1P~ AAEDW ADMUD AHPSJ HZ~ OO~ 0SF AKRWK CGR CUY CVF ECM EIF NPM AAYXX ADVLN AFCTW CITATION 7T5 7TK 7TO 7TS 7U9 H94 K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c612t-4ee982d956154b8ec08dc8de012cb48e355a5b352e0e78a59a9bd7c33cba049b3 |
| ISSN | 0002-9343 |
| IngestDate | Tue Sep 17 21:21:25 EDT 2024 Fri Aug 16 09:07:52 EDT 2024 Thu Aug 29 12:42:34 EDT 2024 Fri Aug 23 02:12:38 EDT 2024 Thu May 23 23:21:43 EDT 2024 Fri Feb 23 02:17:02 EST 2024 Thu Aug 18 17:13:10 EDT 2022 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Adherence Bisphosphonate Hip fracture Osteoporotic fracture Cohort study |
| Language | English |
| License | Copyright © 2015 Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c612t-4ee982d956154b8ec08dc8de012cb48e355a5b352e0e78a59a9bd7c33cba049b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://europepmc.org/articles/pmc4414898?pdf=render |
| PMID | 25660252 |
| PQID | 1682646342 |
| PQPubID | 950 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4414898 proquest_miscellaneous_1677377148 proquest_journals_1682646342 crossref_primary_10_1016_j_amjmed_2015_01_014 pubmed_primary_25660252 elsevier_sciencedirect_doi_10_1016_j_amjmed_2015_01_014 elsevier_clinicalkeyesjournals_1_s2_0_S000293431500087X |
| PublicationCentury | 2000 |
| PublicationDate | 2015-05-01 |
| PublicationDateYYYYMMDD | 2015-05-01 |
| PublicationDate_xml | – month: 05 year: 2015 text: 2015-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: New York |
| PublicationTitle | The American journal of medicine |
| PublicationTitleAlternate | Am J Med |
| PublicationYear | 2015 |
| Publisher | Elsevier Inc Elsevier Sequoia S.A |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier Sequoia S.A |
| References | Gardner, Flik, Mooar, Lane (bib1) 2002; 84-A Nikitovic, Wodchis, Krahn, Cadarette (bib6) 2013; 24 Gedmintas, Solomon, Kim (bib25) 2013; 28 Dixon, Solomon (bib26) 2011; 7 Black, Delmas, Eastell (bib23) 2007; 356 Durie, Katz, Crowley (bib24) 2005; 353 Brauer, Coca-Perraillon, Cutler, Rosen (bib3) 2009; 302 Black, Cummings, Karpf (bib12) 1996; 348 Balasubramanian, Tosi, Lane (bib22) 2014; 96 Wells, Cranney, Peterson (bib13) 2008 Roberts, Goldacre (bib4) 2003; 327 Ensrud, Black, Palermo (bib11) 1997; 157 Lyles, Colon-Emeric, Magaziner (bib8) 2007; 357 Bondo, Eiken, Abrahamsen (bib9) 2013; 24 Teng, Curtis, Saag (bib2) 2009; 7 Dy, McCollister, Lubarsky, Lane (bib5) 2011; 93 Rabenda, Vanoverloop, Fabri (bib17) 2008; 90 Curtis, Yun, Matthews (bib27) 2012; 64 Scaglione, Fabbri, Di Rollo (bib20) 2013; 10 Prieto-Alhambra, Judge, Arden (bib10) 2014; 25 Accessed November 6, 2013. Eisman, Bogoch, Dell (bib19) 2012; 27 Colon-Emeric, Nordsletten, Olson (bib21) 2011; 22 Solomon, Johnston, Boytsov (bib18) 2014; 29 Sampalis, Adachi, Rampakakis (bib29) 2012; 27 Johnell, Kanis (bib7) 2006; 17 Accessed November 5, 2013. Florence R, Allen S, Benedict L, et al. Diagnosis and treatment of osteoporosis (July 2013). Available at Giangregorio, Papaioannou, Cranney (bib16) 2006; 35 National Osteoporosis Foundation. Cinician's guide to prevention and treatment of osteoporosis (2013). Available at Olsen, Hansen, Abrahamsen (bib28) 2013; 24 24695929 - J Bone Joint Surg Am. 2014 Apr 2;96(7):e52 23812596 - Osteoporos Int. 2014 Jan;25(1):77-83 22638712 - Osteoporos Int. 2013 Jan;24(1):245-52 24535775 - J Bone Miner Res. 2014 Sep;29(9):1929-37 16000365 - N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102 22328117 - Arthritis Care Res (Hoboken). 2012 Jul;64(7):1054-60 8950879 - Lancet. 1996 Dec 7;348(9041):1535-41 18253985 - Cochrane Database Syst Rev. 2008 Jan 23;(1):CD001155 21537362 - Nat Rev Rheumatol. 2011 Jun;7(6):369-72 19826027 - JAMA. 2009 Oct 14;302(14):1573-9 21153021 - Osteoporos Int. 2011 Aug;22(8):2329-36 16616152 - Semin Arthritis Rheum. 2006 Apr;35(5):293-305 21976304 - J Bone Miner Res. 2012 Jan;27(1):202-10 17476007 - N Engl J Med. 2007 May 3;356(18):1809-22 23408697 - J Bone Miner Res. 2013 Aug;28(8):1729-37 23604250 - Osteoporos Int. 2013 Oct;24(10):2639-47 22736067 - Osteoporos Int. 2013 Feb;24(2):659-69 19239827 - Curr Osteoporos Rep. 2009 Mar;7(1):27-34 18829912 - J Bone Joint Surg Am. 2008 Oct;90(10):2142-8 9531231 - Arch Intern Med. 1997 Dec 8-22;157(22):2617-24 14525871 - BMJ. 2003 Oct 4;327(7418):771-5 17878149 - N Engl J Med. 2007 Nov 1;357(18):1799-809 12177263 - J Bone Joint Surg Am. 2002 Aug;84-A(8):1342-8 16983459 - Osteoporos Int. 2006 Dec;17(12):1726-33 22836222 - J Bone Miner Res. 2012 Oct;27(10):2039-46 24133530 - Clin Cases Miner Bone Metab. 2013 May;10(2):124-8 21792499 - J Bone Joint Surg Am. 2011 Jul 20;93(14):1326-34 Gedmintas (10.1016/j.amjmed.2015.01.014_bib25) 2013; 28 Solomon (10.1016/j.amjmed.2015.01.014_bib18) 2014; 29 Rabenda (10.1016/j.amjmed.2015.01.014_bib17) 2008; 90 Nikitovic (10.1016/j.amjmed.2015.01.014_bib6) 2013; 24 Balasubramanian (10.1016/j.amjmed.2015.01.014_bib22) 2014; 96 Curtis (10.1016/j.amjmed.2015.01.014_bib27) 2012; 64 Brauer (10.1016/j.amjmed.2015.01.014_bib3) 2009; 302 Teng (10.1016/j.amjmed.2015.01.014_bib2) 2009; 7 Sampalis (10.1016/j.amjmed.2015.01.014_bib29) 2012; 27 Prieto-Alhambra (10.1016/j.amjmed.2015.01.014_bib10) 2014; 25 Eisman (10.1016/j.amjmed.2015.01.014_bib19) 2012; 27 Bondo (10.1016/j.amjmed.2015.01.014_bib9) 2013; 24 Lyles (10.1016/j.amjmed.2015.01.014_bib8) 2007; 357 Black (10.1016/j.amjmed.2015.01.014_bib23) 2007; 356 10.1016/j.amjmed.2015.01.014_bib14 10.1016/j.amjmed.2015.01.014_bib15 Roberts (10.1016/j.amjmed.2015.01.014_bib4) 2003; 327 Gardner (10.1016/j.amjmed.2015.01.014_bib1) 2002; 84-A Dixon (10.1016/j.amjmed.2015.01.014_bib26) 2011; 7 Dy (10.1016/j.amjmed.2015.01.014_bib5) 2011; 93 Olsen (10.1016/j.amjmed.2015.01.014_bib28) 2013; 24 Johnell (10.1016/j.amjmed.2015.01.014_bib7) 2006; 17 Wells (10.1016/j.amjmed.2015.01.014_bib13) 2008 Scaglione (10.1016/j.amjmed.2015.01.014_bib20) 2013; 10 Giangregorio (10.1016/j.amjmed.2015.01.014_bib16) 2006; 35 Colon-Emeric (10.1016/j.amjmed.2015.01.014_bib21) 2011; 22 Ensrud (10.1016/j.amjmed.2015.01.014_bib11) 1997; 157 Black (10.1016/j.amjmed.2015.01.014_bib12) 1996; 348 Durie (10.1016/j.amjmed.2015.01.014_bib24) 2005; 353 |
| References_xml | – volume: 356 start-page: 1809 year: 2007 end-page: 1822 ident: bib23 article-title: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis publication-title: N Engl J Med contributor: fullname: Eastell – volume: 90 start-page: 2142 year: 2008 end-page: 2148 ident: bib17 article-title: Low incidence of anti-osteoporosis treatment after hip fracture publication-title: J Bone Joint Surg Am contributor: fullname: Fabri – volume: 17 start-page: 1726 year: 2006 end-page: 1733 ident: bib7 article-title: An estimate of the worldwide prevalence and disability associated with osteoporotic fractures publication-title: Osteoporos Int contributor: fullname: Kanis – volume: 35 start-page: 293 year: 2006 end-page: 305 ident: bib16 article-title: Fragility fractures and the osteoporosis care gap: an international phenomenon publication-title: Semin Arthritis Rheum contributor: fullname: Cranney – volume: 7 start-page: 369 year: 2011 end-page: 372 ident: bib26 article-title: Bisphosphonates and esophageal cancer—a pathway through the confusion publication-title: Nat Rev Rheumatol contributor: fullname: Solomon – volume: 27 start-page: 202 year: 2012 end-page: 210 ident: bib29 article-title: Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence publication-title: J Bone Miner Res contributor: fullname: Rampakakis – volume: 29 start-page: 1929 year: 2014 end-page: 1937 ident: bib18 article-title: Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011 publication-title: J Bone Miner Res contributor: fullname: Boytsov – volume: 357 start-page: nihpa40967 year: 2007 ident: bib8 article-title: Zoledronic acid in reducing clinical fracture and mortality after hip fracture publication-title: N Engl J Med contributor: fullname: Magaziner – volume: 27 start-page: 2039 year: 2012 end-page: 2046 ident: bib19 article-title: Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention publication-title: J Bone Miner Res contributor: fullname: Dell – volume: 157 start-page: 2617 year: 1997 end-page: 2624 ident: bib11 article-title: Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial publication-title: Arch Intern Med contributor: fullname: Palermo – volume: 84-A start-page: 1342 year: 2002 end-page: 1348 ident: bib1 article-title: Improvement in the undertreatment of osteoporosis following hip fracture publication-title: J Bone Joint Surg Am contributor: fullname: Lane – volume: 327 start-page: 771 year: 2003 end-page: 775 ident: bib4 article-title: Time trends and demography of mortality after fractured neck of femur in an English population, 1968-98: database study publication-title: BMJ contributor: fullname: Goldacre – volume: 96 start-page: e52 year: 2014 ident: bib22 article-title: Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009 publication-title: J Bone Joint Surg Am contributor: fullname: Lane – volume: 24 start-page: 2639 year: 2013 end-page: 2647 ident: bib28 article-title: Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs—an analysis using national health databases publication-title: Osteoporos Int contributor: fullname: Abrahamsen – volume: 22 start-page: 2329 year: 2011 end-page: 2336 ident: bib21 article-title: Association between timing of zoledronic acid infusion and hip fracture healing publication-title: Osteoporos Int contributor: fullname: Olson – volume: 353 start-page: 99 year: 2005 end-page: 102 ident: bib24 article-title: Osteonecrosis of the jaw and bisphosphonates publication-title: N Engl J Med contributor: fullname: Crowley – volume: 348 start-page: 1535 year: 1996 end-page: 1541 ident: bib12 article-title: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group publication-title: Lancet contributor: fullname: Karpf – start-page: CD001155 year: 2008 ident: bib13 article-title: Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women publication-title: Cochrane Database Syst Rev contributor: fullname: Peterson – volume: 64 start-page: 1054 year: 2012 end-page: 1060 ident: bib27 article-title: Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population publication-title: Arthritis Care Res (Hoboken) contributor: fullname: Matthews – volume: 24 start-page: 245 year: 2013 end-page: 252 ident: bib9 article-title: Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study publication-title: Osteoporos Int contributor: fullname: Abrahamsen – volume: 10 start-page: 124 year: 2013 end-page: 128 ident: bib20 article-title: The second hip fracture in osteoporotic patients: not only an orthopaedic matter publication-title: Clin Cases Miner Bone Metab contributor: fullname: Di Rollo – volume: 28 start-page: 1729 year: 2013 end-page: 1737 ident: bib25 article-title: Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis publication-title: J Bone Miner Res contributor: fullname: Kim – volume: 25 start-page: 77 year: 2014 end-page: 83 ident: bib10 article-title: Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial publication-title: Osteoporos Int contributor: fullname: Arden – volume: 7 start-page: 27 year: 2009 end-page: 34 ident: bib2 article-title: Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job? publication-title: Curr Osteoporos Rep contributor: fullname: Saag – volume: 302 start-page: 1573 year: 2009 end-page: 1579 ident: bib3 article-title: Incidence and mortality of hip fractures in the United States publication-title: JAMA contributor: fullname: Rosen – volume: 24 start-page: 659 year: 2013 end-page: 669 ident: bib6 article-title: Direct health-care costs attributed to hip fractures among seniors: a matched cohort study publication-title: Osteoporos Int contributor: fullname: Cadarette – volume: 93 start-page: 1326 year: 2011 end-page: 1334 ident: bib5 article-title: An economic evaluation of a systems-based strategy to expedite surgical treatment of hip fractures publication-title: J Bone Joint Surg Am contributor: fullname: Lane – volume: 90 start-page: 2142 issue: 10 year: 2008 ident: 10.1016/j.amjmed.2015.01.014_bib17 article-title: Low incidence of anti-osteoporosis treatment after hip fracture publication-title: J Bone Joint Surg Am doi: 10.2106/JBJS.G.00864 contributor: fullname: Rabenda – volume: 22 start-page: 2329 issue: 8 year: 2011 ident: 10.1016/j.amjmed.2015.01.014_bib21 article-title: Association between timing of zoledronic acid infusion and hip fracture healing publication-title: Osteoporos Int doi: 10.1007/s00198-010-1473-1 contributor: fullname: Colon-Emeric – volume: 327 start-page: 771 issue: 7418 year: 2003 ident: 10.1016/j.amjmed.2015.01.014_bib4 article-title: Time trends and demography of mortality after fractured neck of femur in an English population, 1968-98: database study publication-title: BMJ doi: 10.1136/bmj.327.7418.771 contributor: fullname: Roberts – volume: 27 start-page: 202 issue: 1 year: 2012 ident: 10.1016/j.amjmed.2015.01.014_bib29 article-title: Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence publication-title: J Bone Miner Res doi: 10.1002/jbmr.533 contributor: fullname: Sampalis – volume: 302 start-page: 1573 issue: 14 year: 2009 ident: 10.1016/j.amjmed.2015.01.014_bib3 article-title: Incidence and mortality of hip fractures in the United States publication-title: JAMA doi: 10.1001/jama.2009.1462 contributor: fullname: Brauer – ident: 10.1016/j.amjmed.2015.01.014_bib14 – volume: 28 start-page: 1729 issue: 8 year: 2013 ident: 10.1016/j.amjmed.2015.01.014_bib25 article-title: Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis publication-title: J Bone Miner Res doi: 10.1002/jbmr.1893 contributor: fullname: Gedmintas – volume: 27 start-page: 2039 year: 2012 ident: 10.1016/j.amjmed.2015.01.014_bib19 article-title: Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention publication-title: J Bone Miner Res doi: 10.1002/jbmr.1698 contributor: fullname: Eisman – volume: 17 start-page: 1726 issue: 12 year: 2006 ident: 10.1016/j.amjmed.2015.01.014_bib7 article-title: An estimate of the worldwide prevalence and disability associated with osteoporotic fractures publication-title: Osteoporos Int doi: 10.1007/s00198-006-0172-4 contributor: fullname: Johnell – volume: 348 start-page: 1535 year: 1996 ident: 10.1016/j.amjmed.2015.01.014_bib12 article-title: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group publication-title: Lancet doi: 10.1016/S0140-6736(96)07088-2 contributor: fullname: Black – volume: 29 start-page: 1929 year: 2014 ident: 10.1016/j.amjmed.2015.01.014_bib18 article-title: Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011 publication-title: J Bone Miner Res doi: 10.1002/jbmr.2202 contributor: fullname: Solomon – volume: 356 start-page: 1809 issue: 18 year: 2007 ident: 10.1016/j.amjmed.2015.01.014_bib23 article-title: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis publication-title: N Engl J Med doi: 10.1056/NEJMoa067312 contributor: fullname: Black – volume: 84-A start-page: 1342 issue: 8 year: 2002 ident: 10.1016/j.amjmed.2015.01.014_bib1 article-title: Improvement in the undertreatment of osteoporosis following hip fracture publication-title: J Bone Joint Surg Am doi: 10.2106/00004623-200208000-00008 contributor: fullname: Gardner – volume: 357 start-page: nihpa40967 year: 2007 ident: 10.1016/j.amjmed.2015.01.014_bib8 article-title: Zoledronic acid in reducing clinical fracture and mortality after hip fracture publication-title: N Engl J Med doi: 10.1056/NEJMoa074941 contributor: fullname: Lyles – volume: 10 start-page: 124 issue: 2 year: 2013 ident: 10.1016/j.amjmed.2015.01.014_bib20 article-title: The second hip fracture in osteoporotic patients: not only an orthopaedic matter publication-title: Clin Cases Miner Bone Metab contributor: fullname: Scaglione – volume: 157 start-page: 2617 issue: 22 year: 1997 ident: 10.1016/j.amjmed.2015.01.014_bib11 article-title: Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial publication-title: Arch Intern Med doi: 10.1001/archinte.1997.00440430099012 contributor: fullname: Ensrud – volume: 96 start-page: e52 issue: 7 year: 2014 ident: 10.1016/j.amjmed.2015.01.014_bib22 article-title: Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009 publication-title: J Bone Joint Surg Am doi: 10.2106/JBJS.L.01781 contributor: fullname: Balasubramanian – volume: 7 start-page: 27 issue: 1 year: 2009 ident: 10.1016/j.amjmed.2015.01.014_bib2 article-title: Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job? publication-title: Curr Osteoporos Rep doi: 10.1007/s11914-009-0006-3 contributor: fullname: Teng – volume: 24 start-page: 659 issue: 2 year: 2013 ident: 10.1016/j.amjmed.2015.01.014_bib6 article-title: Direct health-care costs attributed to hip fractures among seniors: a matched cohort study publication-title: Osteoporos Int doi: 10.1007/s00198-012-2034-6 contributor: fullname: Nikitovic – start-page: CD001155 issue: 1 year: 2008 ident: 10.1016/j.amjmed.2015.01.014_bib13 article-title: Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women publication-title: Cochrane Database Syst Rev contributor: fullname: Wells – volume: 35 start-page: 293 issue: 5 year: 2006 ident: 10.1016/j.amjmed.2015.01.014_bib16 article-title: Fragility fractures and the osteoporosis care gap: an international phenomenon publication-title: Semin Arthritis Rheum doi: 10.1016/j.semarthrit.2005.11.001 contributor: fullname: Giangregorio – volume: 24 start-page: 2639 issue: 10 year: 2013 ident: 10.1016/j.amjmed.2015.01.014_bib28 article-title: Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs—an analysis using national health databases publication-title: Osteoporos Int doi: 10.1007/s00198-013-2365-y contributor: fullname: Olsen – volume: 24 start-page: 245 issue: 1 year: 2013 ident: 10.1016/j.amjmed.2015.01.014_bib9 article-title: Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study publication-title: Osteoporos Int doi: 10.1007/s00198-012-2024-8 contributor: fullname: Bondo – volume: 93 start-page: 1326 issue: 14 year: 2011 ident: 10.1016/j.amjmed.2015.01.014_bib5 article-title: An economic evaluation of a systems-based strategy to expedite surgical treatment of hip fractures publication-title: J Bone Joint Surg Am doi: 10.2106/JBJS.I.01132 contributor: fullname: Dy – ident: 10.1016/j.amjmed.2015.01.014_bib15 – volume: 25 start-page: 77 issue: 1 year: 2014 ident: 10.1016/j.amjmed.2015.01.014_bib10 article-title: Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial publication-title: Osteoporos Int doi: 10.1007/s00198-013-2420-8 contributor: fullname: Prieto-Alhambra – volume: 7 start-page: 369 issue: 6 year: 2011 ident: 10.1016/j.amjmed.2015.01.014_bib26 article-title: Bisphosphonates and esophageal cancer—a pathway through the confusion publication-title: Nat Rev Rheumatol doi: 10.1038/nrrheum.2011.60 contributor: fullname: Dixon – volume: 64 start-page: 1054 issue: 7 year: 2012 ident: 10.1016/j.amjmed.2015.01.014_bib27 article-title: Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population publication-title: Arthritis Care Res (Hoboken) contributor: fullname: Curtis – volume: 353 start-page: 99 issue: 1 year: 2005 ident: 10.1016/j.amjmed.2015.01.014_bib24 article-title: Osteonecrosis of the jaw and bisphosphonates publication-title: N Engl J Med doi: 10.1056/NEJM200507073530120 contributor: fullname: Durie |
| SSID | ssj0000956 |
| Score | 2.497409 |
| Snippet | Abstract Background Although current osteoporosis management guidelines recommend use of pharmacologic treatment after hip fracture, the care of such patients... Although current osteoporosis management guidelines recommend use of pharmacologic treatment after hip fracture, the care of such patients has been suboptimal.... BACKGROUNDAlthough current osteoporosis management guidelines recommend use of pharmacologic treatment after hip fracture, the care of such patients has been... |
| SourceID | pubmedcentral proquest crossref pubmed elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 519 |
| SubjectTerms | Adherence Aged Aged, 80 and over Bisphosphonate Bone Density Conservation Agents - therapeutic use Cohort study Comorbidity Diphosphonates - therapeutic use Female Fractures Hip fracture Hip Fractures - epidemiology Hip Fractures - therapy Hospitalization Humans Internal Medicine Male Medical research Osteoporosis Osteoporotic fracture Osteoporotic Fractures - epidemiology Osteoporotic Fractures - prevention & control Patient admissions Republic of Korea - epidemiology Secondary Prevention Spain - epidemiology United States - epidemiology |
| Title | Use of Osteoporosis Medications after Hospitalization for Hip Fracture: A Cross-national Study |
| URI | https://www.clinicalkey.es/playcontent/1-s2.0-S000293431500087X https://dx.doi.org/10.1016/j.amjmed.2015.01.014 https://www.ncbi.nlm.nih.gov/pubmed/25660252 https://www.proquest.com/docview/1682646342/abstract/ https://search.proquest.com/docview/1677377148 https://pubmed.ncbi.nlm.nih.gov/PMC4414898 |
| Volume | 128 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJiFeJu4UBjISbyhVk9ixzVs1wapNBYmuok9YtuuIVpBMaysBP4jfyXHspGk7BEyqojaXJvH5fHzuB6FXVjhni9KR4SZzLcxgzgmdRzaesVhZxq119o7R-2w4IWdTOu10frWiltYr3TM_r80ruQlVYR_Q1WXJ_gdlmz-FHfAd6AtboDBs_4nGE2-I_wCUKkGOLl1xEe958fFtvgF43RokZFxWgYXD-aWTWSv_QUhOd8tl1NgGx03Z2cUGT417p1VvYtc5H9ozj235wzGS1ye9nSOjeTSuJXtn2lFF7r31X-ffo1PXbKCy3p4qDVp8E_8xDqHDQ9cb6WzeNlbEdBMa6C1odRbNVpBnxZVF6ss19WxgxJRGrrrVFqdOeAuStMV3aeC7fgmnSdaz8bULhLdVLHrq2wLGx4X2-bKtPpN1p_T22D2Ze7DYtY3gbHoLHSZMUFDyDwfnHz-db9Z8UfUJbt6kTtKsIgn37_UnIWhfydmN1W0JPxd30VHQWvDAQ_Ae6tjiPro9CqR_gD4DEnGZ4zYScQuJuEIi3kEiBiRiQCKukfgGD_A2DnGFw4do8u7txckwCp07IgMS8yoi1gqezFzSNCWaW9PnM8NnFqQhowm3IOQqqkH2t31gB4oKJfSMmTQ1WoHKqtNH6KAoC_sE4TzXVOjYmEyDckESDfqIEQkzytAkN1kXRfVQyktfoEXWkYsL6YdeuqGX_Rg-pItYPd6yTj6G5dIuw8xZylguE9mXe8RvXxnEUy92SgDXX-55XBNWbm6TgWZPspQkXfSyOQzM3XnsVGHLtTuHsZSxmPAueuxx0Lwk6CoZKCxwNdtCSHOCKxy_faSYf6kKyIMKRLjgT2_8Qs_QHfhFvCnyGB2srtb2OQjnK_0izIzfhcvnCg |
| link.rule.ids | 230,315,786,790,891,27957,27958 |
| linkProvider | Library Specific Holdings |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+Osteoporosis+Medications+after+Hospitalization+for+Hip+Fracture%3A+A+Cross-national+Study&rft.jtitle=The+American+journal+of+medicine&rft.au=Kim%2C+Seoyoung+C.&rft.au=Kim%2C+Mi-Sook&rft.au=Sanf%C3%A9lix-Gimeno%2C+Gabriel&rft.au=Song%2C+Hong+Ji&rft.date=2015-05-01&rft.pub=Elsevier+Inc&rft.issn=0002-9343&rft.eissn=1555-7162&rft.volume=128&rft.issue=5&rft.spage=519&rft.epage=526.e1&rft_id=info:doi/10.1016%2Fj.amjmed.2015.01.014&rft.externalDocID=S000293431500087X |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00029343%2FS0002934314X00070%2Fcov150h.gif |